Albert Bourla, Pfizer CEO (Michel Euler/AP Images, Pool)
May 31, 2023 05:58 PM EDTUpdated June 1, 11:02 AM
Pharma
FDA+

FDA ap­proves Pfiz­er’s RSV shot for old­er adults, tee­ing up a com­pet­i­tive $17B vac­cine mar­ket

Andrew Dunn

Senior Biopharma Correspondent

The FDA ap­proved Pfiz­er’s RSV vac­cine called Abrys­vo for old­er adults on Wednes­day, plac­ing an­oth­er Big Phar­ma on­to the com­mer­cial stage ahead of the next …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times